Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | BRS3 | P32247 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ERN1 | O75460 | 2/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548048 | 0.90 | RAB9A (0.36) | RAB9ABRS3POLBHPGDSMN1; SMN2 | |
| SCHEMBL28456611 | 0.79 | KDM4E (0.46) | RAB9ABRS3POLBHPGDSMN1; SMN2 | |
| SCHEMBL9953769 | 0.79 | RAB9A (0.37) | RAB9ABRS3POLBHPGDSMN1; SMN2 | |
| SCHEMBL27773816 | 0.79 | GAA (0.37) | RAB9ABRS3POLBHPGDSMN1; SMN2 | |
| SCHEMBL27706541 | 0.77 | SIRT3 (0.47) | RAB9ABRS3POLBHPGDSMN1; SMN2 | |
| SCHEMBL27773717 | 0.77 | ROCK2 (0.38) | RAB9ABRS3POLBHPGDSMN1; SMN2 | |
| SCHEMBL27667487 | 0.77 | RAB9A (0.37) | RAB9ABRS3POLBHPGDSMN1; SMN2 | |
| SCHEMBL9952196 | 0.75 | CYP1A2 (0.36) | RAB9ABRS3POLBHPGDSMN1; SMN2 | |
| SCHEMBL28264077 | 0.75 | RAB9A (0.37) | RAB9ABRS3POLBHPGDSMN1; SMN2 | |
| SCHEMBL9939364 | 0.73 | GAA (0.38) | RAB9APOLBHPGDSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198282-B2 | Substituted azaquinazolines having an antiviral action | AICURIS GMBH & CO. KG (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20100179174-A1 | SUBSTITUTED AZAQUINAZOLINES HAVING AN ANTIVIRAL ACTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | US | disclosed |
| US-7662822-B2 | Substituted azaquinazolines having an antiviral action | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-16 | — | — | US | disclosed |
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | BAYER HEALTHCARE AG (DE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132515-A1 | antiviral agents, in particular against cytomegaloviruses; {2-[4-(4-Fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrido[3,4-d]-pyrimidin-4-yl}acetic acid hydrochloride | ZC3HAV1, EIF2AK2, IRF3 | RAB9A 1869/4885BRS3 4684/4885POLB 201/4885 |
| US-20100179174-A1 | SUBSTITUTED AZAQUINAZOLINES HAVING AN ANTIVIRAL ACTION | EIF2AK2, TPMT, IRF3 | RAB9A 1434/4885BRS3 3729/4885POLB 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.